Use of data from multiple registries in studying biologic discontinuation: challenges and opportunities.
暂无分享,去创建一个
M. Weinblatt | D. Solomon | S. Bae | A. Kavanaugh | M. Okada | S. Tohma | M. Kishimoto | Y. Sung | Kazuki Yoshida | H. Radner | K. Matsui | K. Yoshida
[1] M. Weinblatt,et al. Biologic discontinuation studies: a systematic review of methods , 2013, Annals of the rheumatic diseases.
[2] Y. Saeki,et al. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study , 2013, Modern rheumatology.
[3] A. Boonen,et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries , 2013, Annals of the rheumatic diseases.
[4] H. Yamanaka,et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: Postmarketing surveillance report of 7740 patients , 2012, Modern rheumatology.
[5] Seoyoung C. Kim,et al. Changes in Use of Disease‐Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States During 1983–2009 , 2013, Arthritis care & research.
[6] K. Pavelka,et al. Biologic registries in rheumatology: lessons learned and expectations for the future. , 2012, Autoimmunity reviews.
[7] H. Yamanaka,et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients , 2012, Modern rheumatology.
[8] A. Vignoli,et al. Rett networked database: An integrated clinical and genetic network of rett syndrome databases , 2012, Human mutation.
[9] S. Bang,et al. Korean Observational Study Network for Arthritis (KORONA): establishment of a prospective multicenter cohort for rheumatoid arthritis in South Korea. , 2012, Seminars in arthritis and rheumatism.
[10] J. Smolen,et al. Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index , 2012, Annals of the rheumatic diseases.
[11] P. V. van Riel,et al. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration , 2011, Annals of the rheumatic diseases.
[12] H. Yamanaka,et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients , 2011, Annals of the rheumatic diseases.
[13] Parminder Raina,et al. Invited commentary: consolidating data harmonization--how to obtain quality and applicability? , 2011, American journal of epidemiology.
[14] M. Weinblatt,et al. Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study , 2011, Arthritis research & therapy.
[15] J. Douwes,et al. AGRICOH: A Consortium of Agricultural Cohorts , 2011, International journal of environmental research and public health.
[16] E. Nasonov,et al. Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries , 2011, Medical science monitor : international medical journal of experimental and clinical research.
[17] H. Yamanaka,et al. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis , 2011, Modern rheumatology.
[18] Jing Cui,et al. Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study. , 2011, Rheumatology.
[19] N. Dreyer,et al. Registries for Evaluating Patient Outcomes: A User’s Guide , 2010 .
[20] N. Nishimoto,et al. Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study , 2010, Modern rheumatology.
[21] B. Bresnihan,et al. Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST–RA database , 2009, Annals of the rheumatic diseases.
[22] Kevin B. Johnson,et al. Categorizing the world of registries , 2008, J. Biomed. Informatics.
[23] J. Kremer,et al. The role of drug and disease registries in rheumatic disease epidemiology , 2008, Current opinion in rheumatology.
[24] H. Yamanaka,et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis , 2007, Annals of the rheumatic diseases.
[25] H. Yamanaka,et al. Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values , 2006, Annals of the rheumatic diseases.
[26] H. Yamanaka,et al. Potential impact of observational cohort studies in Japan on rheumatoid arthritis research and practice , 2006, Modern rheumatology.
[27] J. Kremer. The CORRONA database , 2005, Annals of the rheumatic diseases.
[28] Gary H Lyman,et al. The strengths and limitations of meta-analyses based on aggregate data , 2005, BMC Medical Research Methodology.
[29] J. Ware,et al. Applied Longitudinal Analysis , 2004 .
[30] W. Ray,et al. Evaluating medication effects outside of clinical trials: new-user designs. , 2003, American journal of epidemiology.
[31] A. Silman,et al. British Society for Rheumatology Biologics Register , 2003, Annals of the rheumatic diseases.
[32] T. Pincus. Limitations of randomized clinical trials in chronic diseases: explanations and recommendations. , 2002, Advances in mind-body medicine.
[33] T. Pincus,et al. Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: some explanations and suggestions for future studies. , 1997, Clinical and experimental rheumatology.
[34] L. Moses. The series of consecutive cases as a device for assessing outcomes of intervention. , 1984, The New England journal of medicine.
[35] Rupert G. Miller,et al. Survival Analysis , 2022, The SAGE Encyclopedia of Research Design.